Nanobac Pharmaceuticals Incorporated Stock Performance
| NNBP Stock | USD 0.0001 0.00 0.00% |
The company secures a Beta (Market Risk) of 0.0, which conveys not very significant fluctuations relative to the market. the returns on MARKET and Nanobac Pharmaceuticals are completely uncorrelated.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Nanobac Pharmaceuticals Incorporated has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable fundamental drivers, Nanobac Pharmaceuticals is not utilizing all of its potentials. The current stock price agitation, may contribute to short-term losses for the retail investors. ...more
Last Split Factor 1:4 | Last Split Date 2000-03-27 |
| Total Cashflows From Investing Activities | 48.6 K |
Nanobac |
Nanobac Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 0.01 in Nanobac Pharmaceuticals Incorporated on September 3, 2024 and sell it today you would earn a total of 0.00 from holding Nanobac Pharmaceuticals Incorporated or generate 0.0% return on investment over 90 days. Nanobac Pharmaceuticals Incorporated is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Nanobac, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Nanobac Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Nanobac Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Nanobac Pharmaceuticals Incorporated, and traders can use it to determine the average amount a Nanobac Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| NNBP |
Based on monthly moving average Nanobac Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Nanobac Pharmaceuticals by adding Nanobac Pharmaceuticals to a well-diversified portfolio.
Nanobac Pharmaceuticals Fundamentals Growth
Nanobac Stock prices reflect investors' perceptions of the future prospects and financial health of Nanobac Pharmaceuticals, and Nanobac Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Nanobac Stock performance.
| Return On Asset | -0.37 | ||||
| Operating Margin | (151.42) % | ||||
| Current Valuation | 124.75 K | ||||
| Price To Earning | (0.02) X | ||||
| Price To Sales | 7.08 X | ||||
| Revenue | 17.62 K | ||||
| Gross Profit | 3.1 K | ||||
| EBITDA | (3.97 M) | ||||
| Net Income | (6.58 M) | ||||
| Cash And Equivalents | 3.93 K | ||||
| Total Debt | 4.12 M | ||||
| Book Value Per Share | (0.01) X | ||||
| Cash Flow From Operations | (910.89 K) | ||||
| Market Capitalization | 124.75 K | ||||
| Total Asset | 7.22 M | ||||
| Retained Earnings | (28.93 M) | ||||
| Working Capital | (6.71 M) | ||||
| Current Asset | 31 K | ||||
| Current Liabilities | 6.75 M | ||||
About Nanobac Pharmaceuticals Performance
Assessing Nanobac Pharmaceuticals' fundamental ratios provides investors with valuable insights into Nanobac Pharmaceuticals' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Nanobac Pharmaceuticals is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 233.11 | 168.33 | |
| Return On Tangible Assets | (97.85) | (92.96) | |
| Return On Capital Employed | 9.33 | 9.79 | |
| Return On Assets | (1.05) | (1.10) | |
| Return On Equity | 2.51 | 2.63 |
Things to note about Nanobac Pharmaceuticals performance evaluation
Checking the ongoing alerts about Nanobac Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Nanobac Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Nanobac Pharmaceuticals generated a negative expected return over the last 90 days | |
| Nanobac Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Nanobac Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 17.62 K. Net Loss for the year was (6.58 M) with profit before overhead, payroll, taxes, and interest of 3.1 K. | |
| Nanobac Pharmaceuticals Incorporated currently holds about 3.93 K in cash with (910.89 K) of positive cash flow from operations. | |
| Nanobac Pharmaceuticals has a very weak financial position based on the latest SEC disclosures |
- Analyzing Nanobac Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Nanobac Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Nanobac Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Nanobac Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Nanobac Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Nanobac Pharmaceuticals' stock. These opinions can provide insight into Nanobac Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Nanobac Stock Analysis
When running Nanobac Pharmaceuticals' price analysis, check to measure Nanobac Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nanobac Pharmaceuticals is operating at the current time. Most of Nanobac Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Nanobac Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nanobac Pharmaceuticals' price. Additionally, you may evaluate how the addition of Nanobac Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.